|
|
|
| The Randomized Placebo-controlled Trial of Deoxynucleotide Injection Combined with Chemotherapy in Treatment of Middle-late Non-small Cell Lung Cancer |
| Nanping First Hospital of Fujian Medical University， Nanping 353000，China |
|
|
|
Abstract Objective： To observe and compare the clinical efficacy and adverse reaction of deoxynucleotide injection combined with chemotherapy in of human middle-late non-small cell lung cancer. Method： 62 cases of nonsmall cell lung cancer patients were selected by multicenter and randomized controlled clinical trial method from March 2013 to March 2014. All patients were divided into two groups，the control group of 32 cases who were treated with chemotherapy and granulocyte colony-stimulating factor， and the experimental group of 30 cases who were treated with deoxynucleotide injection 200 mg/d on the base of control group.After 2，7，14 d continuous treatment，the levels of white blood cells and platelet were assessed， the occurrence of III+IV bone marrow suppression was recorded， the immune function，weight，and quality life scores of patients were assessed.Result： The treatment group after 7 d WBC count was （4.2±1.2）×109/L，platelet count was（ 67.4±13.2）×109/L，WBC normal persons accounted for 73.3%，the III+IV
bone marrow suppression rate was 13.3%；the control group was respectively（3.1±1.1）×109/L，（46.8±17.8）×109/L，31.3%，56.3%，the differences were statistically significant（P<0.05）.Followed 14 d， the treatment group of CD3+，CD4+，CD4+/CD8+，NK cells were respectively（ 54.7±8.2）%，（39.2±4.5）%，（31.2±10.2）%，（1.33±0.29）；the control group of CD3+，CD4+，CD4+/CD8+，NK cells were respectively（ 48.3±6.6）%，（31.3±5.0）%，（24.3±8.9）%，（1.01±0.18）， the treatment group’s levels were better than the control group， the differences were statistically significant（P<0.05）. Followed 21 d， the treatment group muscle aches/weakness events，liver injury（ALT，AST，or TBI exception） incidence rate was respectively 6.6%，3.3%，the control group was respectively 40.6%， 21.9%，another treatment group gained an average of（ 1.8±0.3）kg， the control group of（ -0.4±0.2）kg，the differences were statistically significant（P<0.05）.Conclusion： Deoxynucleotide injection reduce the degree of bone marrow suppression caused by chemotherapy， improve the patient’s weight， immune function and quality of life scores.
|
|
|
|
|
|
|
|
|
